Vincerx Pharma

Update in progress

VINC (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vincerx Pharma, Inc. is a clinical-stage biopharma focused on cancer therapies in the United States. Its VersAptx platform enables antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC), plus CellTrapper to reduce payload permeability. It is developing VIP943 (Phase 1 for AML, high-risk MDS, B-ALL), VIP236 (SMDC, Phase 1 for solid tumors), and VIP924 (anti-CXCR5 ADC; preclinical). It collaborates with NIH on enitociclib (CDK9 inhibitor). Founded 2019, based in San Mateo, CA; formerly Vincera Pharma, renamed 2021.

Company score

Sentiment: -0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive